Cytochroma announces positive Phase 1/2 results for CTAP101 capsules in non-dialysis chronic kidney disease patients
Cytochroma announced positive Phase 1/2 results for CTAP101 Capsules, a product being developed to treat secondary hyperparathyroidism (SHPT) associated with vitamin D insufficiency in non-dialysis chronic kidney disease (CKD) patients. The study demonstrated that a single dose of CTAP101 Capsules was safe, effective and well tolerated. The study also demonstrated that the mechanism to lower intact parathyroid hormone (iPTH) levels in CKD patients with vitamin D insufficiency is more complex than simply boosting blood vitamin D levels.
"We have gained significant new insights into the treatment of secondary hyperparathyroidism associated with low blood vitamin D levels in patients with chronic kidney disease," stated Dr. Charles W. Bishop, Cytochroma's President and Chief Executive Officer. "We are pleased to see that a single dose of CTAP101 Capsules resulted in reliable improvement of vitamin D status with meaningful and sustained suppression of elevated intact PTH. Intravenous delivery of the same active ingredient did not lower intact PTH despite restoration of blood vitamin D to adequate levels. The lack of effect of intravenous delivery is consistent with the recent body of evidence built up by Cytochroma's applied research team indicating that mega-doses of vitamin D, the current standard of care for SHPT associated with vitamin D insufficiency, is inefficient and only sporadically effective. Based on the results of this Phase 1/2 study, Cytochroma is looking to advance CTAP101 Capsules into a larger repeat-dose Phase 2 study in CKD patients as rapidly as possible."
The completed trial was a randomized, open-label, single-dose study to evaluate the pharmacokinetics, pharmacodynamics, safety and tolerability of two different oral doses of CTAP101 Capsules and an intravenous dose of the same active ingredient. Twenty-eight patients with stage 3 or 4 CKD were treated in the study having endpoints of blood vitamin D levels, adverse events, physical and clinical laboratory assessments, and changes in serum calcium, phosphorus and iPTH.
The results showed that a single dose of CTAP101 Capsules achieved normalization of mean blood vitamin D levels and a sustained, clinically important reduction in serum iPTH levels. A comparable reduction in iPTH levels was not observed in the group receiving intravenous therapy despite an immediate and greater increase in blood vitamin D levels. Mean serum calcium and phosphorus levels remained in the normal range in all three treatment groups throughout the study. There were no serious adverse events during the study.
Other news from the department research and development
